Crospovidone (PVP XL/CL) is correctly classified as a pharmacopoeial excipient rather than an active pharmaceutical ingredient; its function in tablet, capsule, and granule dosage forms is that of a water-insoluble superdisintegrant. Immediate-release tablet matrices prepared by direct compression preferentially use grades with a median particle size in the 80–130 µm range, while fine CL grades are reserved for low-weight tablets and orally disintegrating platforms. In ternary direct-compression blends with microcrystalline cellulose and spray-dried lactose, a crospovidone concentration of 2–5 wt% is normally sufficient; the disintegrant effect becomes marginal below 2 wt%, and above 8 wt% tablet surface roughness and friability tend to increase because the crosslinked polymer undergoes elastic recovery after compaction. Tablets compressed at 10–18 kN on a rotary press with 10-mm flat-faced bevel-edged punches produce tensile strengths of 1.5–2.5 MPa; disintegration time in 900 mL deionized water at 37 ± 2 °C per USP <701> and Ph. Eur. 2.9.1 remains below 180 s when the disintegrant concentration is above 2.5 wt%. Water uptake proceeds by capillary intrusion into the crosslinked polyvinylpyrrolidone network; hydration capacity measured by the pharmacopoeial method for the selected grade is typically 3.5–5.5 g/g, and the material does not form a viscous gel layer on contact with water. In a bin blender, crospovidone should be blended with the main powder mass before the final magnesium stearate lubrication step, and the lubricant mixing time should be kept under 5 min at 20–30 rpm; extended blending of the lubricated mix can coat the crospovidone surface and increase disintegration time. A production-scale failure mode observed on high-capacity presses is edge capping when the microcrystalline cellulose-to-crospovidone ratio falls below 5:1; reducing pre-compression force from 8 kN to 3 kN or reducing turret speed from 60 rpm to 40 rpm lowers elastic recovery after decompression and restores tablet integrity. Crospovidone XL-type grades with a lower fines fraction generally give less weight variability in force feeders operating at 30–60 rpm paddle speed, while fine CL grades can segregate unless the active and filler particle sizes are matched.

What Limits Intragranular Versus Extragranular Crospovidone in High-Shear Wet Granulation?

If the entire crospovidone quantity is placed inside the wet mass during high-shear granulation, a portion of the disintegrant's dry-state void network is lost before tablet compression. The intragranular fraction absorbs granulating fluid during the massing step and contributes less to disintegration than an equivalent extragranular quantity, so split addition is used: 1–2 wt% intragranular plus 2–3 wt% extragranular is a common working range for crospovidone in high-shear processing. With water as the granulating fluid at a spray rate of 10–30 g/min per kilogram of dry mass, the impeller tip speed in a 65 L high-shear mixer is usually maintained at 5–8 m/s, and the chopper speed is limited to 1000–1500 rpm to avoid rupture of crospovidone agglomerates. Endpoint torque monitoring indicates that crospovidone-containing wet masses reach 8–12 N·m approximately 15–25 s earlier than comparable formulations using croscarmellose sodium, because crospovidone absorbs water rapidly. Drying in a fluid-bed dryer at an inlet air temperature of 50–60 °C and an exhaust temperature of 30–35 °C is acceptable; the residual moisture content after drying should be below 2.0 wt% because retained water in the crosslinked powder reduces the subsequent water uptake during disintegration testing. Tablets compressed from milled granules with 2–5 wt% crospovidone at hardness 60–100 N for a 10-mm round tablet show disintegration times of 300–600 s when the entire disintegrant amount is intragranular, but drop to 120–240 s when 60–70% of the total crospovidone is placed extragranularly. The measured difference is a processing effect rather than a change in polymer chemistry. Crospovidone is chemically stable during wet granulation and can be processed with aqueous or hydroalcoholic binder solutions; however, it is water-insoluble and is excluded from parenteral dosage forms. The exclusion is consistent with USP <788> particulate matter limits for injections, and the injectable-grade povidone used as a soluble plasma expander is linear povidone, not crosslinked PVP XL/CL.

Orally Disintegrating Tablet Platforms and Crospovidone CL Grade Selection

Direct-compression platforms for orally disintegrating tablets use fine crospovidone CL grades with a median particle size below 50 µm because the smaller particles distribute more evenly across the tablet matrix and produce a smooth mouthfeel after wetting. A representative ODT blend contains 4–8 wt% crospovidone CL, 60–85 wt% compactible mannitol, 5–15 wt% microcrystalline cellulose, and 0.5–1.0 wt% sodium stearyl fumarate as lubricant. The compression force is adjusted to 5–10 kN for a 9-mm convex tablet; the resulting tablets show hardness of 30–50 N and friability below 1.0% when tested per USP <1216>. In a USP <701> disintegration apparatus at 37 ± 2 °C, the disintegration time is normally below 30 s when the crospovidone CL concentration is above 5 wt%; a small-volume 5 mL artificial saliva assay at 37 ± 2 °C gives comparable values. The crosslinked polymer maintains a hydration capacity of 3.5–5.5 g/g but does not form a gel; the wetted tablet disintegrates into a soft, non-mucilaginous dispersion. Taste-masking of bitter actives in ODT formulations is achieved by coating the active particles with a methacrylate polymer or by granulating the active into mannitol-based pellets before blending with crospovidone CL; the disintegrant does not disrupt the coated particle integrity in the oral cavity. On a 27-station rotary press, ODT formulations with 6 wt% crospovidone CL can be compressed at 30–50 rpm, but the compression suite must be maintained at 20–25 °C and 20–30% RH. If the relative humidity rises above 60%, the powder picks up moisture, the friability increases, and punch-tip picking may occur within 15–30 min of continuous operation.

In hard gelatin and HPMC capsule fill production, crospovidone is used as an intragranular or extragranular disintegrant in powder fills, roller-compacted granules, and wet-granulated fill masses. A typical capsule fill for a 200 mg active dose contains 2–4 wt% crospovidone, 40–60 wt% direct-compression filler such as lactose monohydrate or dibasic calcium phosphate dihydrate, and 0.25–0.50 wt% magnesium stearate. The fill mass is prepared as a free-flowing granule with a Carr index below 20% and a Hausner ratio below 1.25 measured according to USP <1174> to ensure consistent plug formation on an automatic capsule filling machine operating at 60–100 cycles/min. Crospovidone does not gelatinize in the presence of gelatin or HPMC shell moisture and does not react with residual aldehydes in shell excipients; this is a practical advantage in HPMC systems where shell opening may be slowed by viscous fill plugs. During dissolution testing with USP <711> apparatus 2 at 50–75 rpm in 900 mL of 0.1 N hydrochloric acid at 37 ± 2 °C, capsule formulations containing crospovidone typically show full shell opening within 1–2 min and content dispersion within 10–15 min, provided that the plug density remains below 0.85 g/mL. If the fill mass is over-compressed in the dosing disc or if the lubrication time is extended beyond 15 min, the magnesium stearate film becomes more continuous and water ingress is delayed, increasing content dispersion time to more than 30 min. For low-fill-weight capsules with a small plug mass, 3–5 wt% crospovidone CL fine grade is preferred because it disperses more uniformly; for high-fill-weight capsules with a metering disc thickness of 15–20 mm, XL grade reduces segregation and produces a more uniform disintegrant distribution.

When Crospovidone Is Compacted in Roller Compaction Ribbons

When crospovidone is compacted in a roller compaction ribbon, the retained disintegrant activity depends on ribbon density, roll pressure, and the point of addition. Intragranular addition at 2–5 wt% is compacted with the active and fillers at roll pressures between 5 and 15 kN/cm, roll speeds between 1 and 5 rpm, and gap widths between 1.0 and 2.5 mm. The ribbon density is maintained between 0.9 and 1.2 g/cm³; above 1.2 g/cm³, the crosslinked polyvinylpyrrolidone loses a significant portion of its capillary void volume and the final tablet disintegration time can increase from below 180 s to over 600 s in USP <701> testing. Because crospovidone deforms plastically under compaction load, it retains some porosity after milling, but the retained porosity falls as roll pressure and binder content increase. If the formulation contains 20–30 wt% microcrystalline cellulose as a dry binder, the ribbon can be milled through a 0.8–1.25 mm screen; a brittle formulation with an excessively hard ribbon can generate more than 30% of granules below 75 µm after oscillating granulator milling, leading to poor flow and tablet weight variation. A split addition is used to preserve disintegration speed: 50–70% of the crospovidone is added before roller compaction, and the remaining 30–50% is blended extragranularly after milling. Tablets compressed from such granules at 10–20 kN on a rotary press exhibit tablet tensile strength of 1.8–2.8 MPa and disintegration times of 90–240 s. Crospovidone-containing roller-compacted granules are also used in sachet formulations for oral suspension; the granular dosage form is dispersed in 20–50 mL of water before administration, and the crosslinked disintegrant assists the wetting and break-up of the granule within 60–120 s without creating a viscous gel layer.

Granule-based oral dosage forms for reconstitution in water use crospovidone as a dispersant and disintegrant in dry syrups, effervescent granules, and unit-dose sachets. A typical extra-granular crospovidone concentration of 2–5 wt% is blended into dried granules with a particle size between 0.2 and 0.8 mm; the crosslinked polymer accelerates the break-up of the granule bed when the patient adds 50–100 mL of water at 15–25 °C. Reconstitution with manual stirring for 30–60 s produces a uniform suspension with no gel phase; the crospovidone remains as swollen inert particles and does not dissolve. The hydration capacity of 3.5–5.5 g/g allows rapid capillary wetting even at low water temperature, which is a practical constraint in field use. In dry powder formulations containing hygroscopic actives or sugar-based carriers, the crospovidone grade must be selected for low equilibrium moisture uptake and the bulk powder must be protected from relative humidity above 60% during filling of sachets. Fill weight variation on a stick-pack machine operating at 60–120 packs/min is minimized when the crospovidone fraction is integrated into the final mix after vacuum drying, because fine CL grades can generate dust and static adhesion if added too early. Published data for specific crospovidone-containing sachet products are limited; the ranges given here are formulation development starting points and must be confirmed by batch data.